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assess health-related quality-of-life (HRQOL) outcomes are often
difﬁcult to perform. Researchers must select a target minimal clin-
ically important difference (MCID) in HRQOL for the trial, estimate the
effect size of the intervention, and then consider the responsiveness
of different HRQOL measures for detecting improvements. Generic
preference-based HRQOL measures are usually less sensitive to gains
in HRQOL than are disease-speciﬁc measures, but are nonetheless
recommended to quantify an impact on HRQOL that can be translated
into quality-adjusted life-years during cost-effectiveness analyses. Map-
ping disease-speciﬁc measures onto generic measures is a proposed
method for yielding more efﬁcient sample size requirements while
retaining the ability to generate utility weights for cost-effectiveness
analyses. Objectives: This study sought to test this mapping strategy to
calculate and compare the effect on sample size of three different
methods.Methods: Three different methods were used for determiningee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.11.004
enbaum@umontreal.ca.
ondence to: Cara Tannenbaum, Geriatric Institute
W 1W5.an MCID in HRQOL in patients with incontinence: 1) a global rating of
improvement, 2) an incontinence-speciﬁc HRQOL instrument, and 3) a
generic preference-based HRQOL instrument using mapping coefﬁ-
cients. Results: The sample size required to detect a 20% difference in
the MCID for the global rating of improvement was 52 per trial arm, 172
per arm for the incontinence-speciﬁc HRQOL outcome, and 500 per arm
for the generic preference-based HRQOL outcome. Conclusions: We
caution that treatment trials of conditions for which improvements are
not easy to measure on generic HRQOL instruments will still require
signiﬁcantly greater sample size even whenmapping functions are used
to try to gain efﬁciency.
Keywords: clinical trials, minimal clinically important difference,
quality of life, sample size, urinary incontinence.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Sample size calculations for clinical trials aim to ensure that each
trial will have sufﬁcient statistical power to detect a predeter-
mined difference in the outcome of interest between the new
intervention and the comparator [1]. Participants in each trial
arm usually achieve some degree of clinically important change,
rendering it necessary to quantify the magnitude of effect due to
the intervention alone. A minimal clinically important difference
(MCID) in survival or symptoms is therefore deﬁned in advance
for each participant, and rates of attaining this MCID are com-
pared between groups in the ﬁnal analysis [1–3]. The MCID has
been well established as the principal way of giving clinical
relevance to changes in standardized measures, representingthe smallest difference in a score in the domain of interest that
patients perceive as beneﬁcial in the management of their
condition [3]. A critical component of sample size calculations
for health-related quality-of-life (HRQOL) outcomes is anticipat-
ing the likelihood that participants in each trial arm will reach
their desired MCID in HRQOL.
The National Institute for Health and Care Excellence recom-
mends using a generic preference-based instrument to assess
gains in trial-based quality of life to quantify an impact on
HRQOL that can be converted into quality-adjusted life-years
(QALYs) for evaluation of cost effectiveness, and compared across
the spectrum of disease [4]. Rates of attaining the MCID for a
speciﬁc disease, as deﬁned and measured on a disease-speciﬁc
HRQOL measure, are often attenuated when generic HRQOLociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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different effect sizes by type of instrument and disease category
[5]. Health conditions that preferentially affect domains of mental
health over physical health comprise a disease category for
which effect sizes are more difﬁcult to measure on generic
HRQOL instruments [6]. Instruments such as the three-level
EuroQol ﬁve-dimensional questionnaire (EQ-5D-3L) and the
short-form 36 health survey (SF-36) miss important aspects of
the impact mental health issues can have on the quality of
people’s lives [6]. Mental health effects on self-perception, ill-
being, and activity are insufﬁciently detected by the EQ-5D-3L and
the SF-36 for persons with anxiety disorders, bipolar disorders, and
schizophrenia [6]. Similar shortcomings of generic preference-
based HRQOL measures apply to persons suffering from urinary
incontinence [7–9]. The quality-of-life domains affected by the
experience of involuntary urine loss include social embarrassment,
avoidance behavior, psychosocial impact, and sleep, which have
limited representation in generic preference-based HRQOL meas-
ures [8–11]. In individuals with mild symptoms of incontinence, the
EQ-5D-3L demonstrates a pronounced ceiling effect and skewed
response distribution and has been shown to be relatively insensi-
tive to changes in incontinence severity [7,8].
Poor responsiveness on generic HRQOL instruments results in
the need for a larger sample size to detect clinically important
differences in HRQOL during clinical treatment trials. Lenert et al.
[12] showed in a trial of patients with schizophrenia that the
effect size was reduced by half when the SF-36 was used to
measure HRQOL, compared with a disease-speciﬁc preference-
based HRQOL, increasing by fourfold the requisite sample size to
be able to conﬁrm the desired effect. In a recent review of 38 trials
with cost-utility analyses across various ﬁelds, Hollingworth et al.
[13] found that only 29.5% of clinical trials were adequately
powered to detect a meaningful difference in QALYs between
treatment arms.
Two major challenges encountered during the design phase
of a trial are therefore 1) determination of an appropriate MCID
to be measured by generic preference-based HRQOL outcome
instruments and 2) ﬁnding a strategy for minimizing the sample
size when the generic HRQOL instrument is poorly responsive to
small changes in health status for the condition under study. If
these two issues are ignored, researchers risk underpowering
their trial to detect a meaningful difference in preference-based
HRQOL and health utility values, resulting in indeterminate
cost-utility analyses. Mapping disease-speciﬁc HRQOL instru-
ments onto generic instruments has been proposed as one
solution for determining the MCID in HRQOL and estimating
sample size requirements when generic preference-based
HRQOL instruments are relatively insensitive to changes in the
index health condition [14]. According to Ades et al. [14], the
MCID effect should ﬁrst be measured on the disease-speciﬁc
scale and then mapped onto the generic scale, using power
calculations that take into account the uncertainty surrounding
the mapping coefﬁcient. The theoretical underpinnings of this
approach have previously been described, with the resultant
sample size for the trial dependent on the relative responsive-
ness of the outcome measures and the precision of the mapping
estimate [14,15]. To our knowledge, this method of reaching a
parsimonious sample size for generic preference-based HRQOL
outcomes has never been applied in practice to trial-based
sample size calculations in which it is known a priori that
improvements in preference-based HRQOL will be difﬁcult to
detect with generic measures.
The present article describes our experience of calculating
the sample size during the design phase of an incontinence
treatment trial and compares the effect on the sample size of
three different methods for determining an MCID in HRQOL in
patients with incontinence: 1) a global rating of improvement, 2)an incontinence-speciﬁc HRQOL instrument, and 3) a generic
preference-based HRQOL instrument and mapping coefﬁcients.Methods
Deﬁning the MCID for a Global Rating of Change
Several methods exist for ascertaining an MCID in a patient’s
response to treatment [3,16]. One of the preferred approaches is
to use the patient’s global rating of change. In the ﬁeld of
incontinence, the seven-item Patient Global Impression of
Improvement questionnaire (PGI-I) is a well-validated global
rating of change questionnaire that asks patients to rate their
incontinence status as “very much worse,” “much worse,” “a little
worse,” “no change,” “a little better,” “much better,” or “very
much better” compared with the previous status [17,18]. Ratings
of “much better” or “very much better” on the PGI-I have been
shown to correlate with signiﬁcant improvements in inconti-
nence severity, incontinence-related quality of life, and patient-
reported self-efﬁcacy for preventing urine loss after treatment
[17–20]. In a previous randomized trial of continence promotion
interventions to reduce urinary symptoms in older women, the
difference between the control and intervention groups among
participants endorsing ratings of “much better” or “very much
better” at trial end point was 30% in the intervention group and
6% in the control group (a difference of 23% in proportions; 95%
conﬁdence interval 10%–36%) [19]. We decided to justify our
sample size calculation for a new incontinence treatment trial
with older women by aiming to replicate a minimal 20% differ-
ence in the proportion of participants who achieved an MCID of
“much better” or “very much better” on the PGI-I.
Deﬁning an MCID for Incontinence-Speciﬁc HRQOL
The Incontinence Quality of Life questionnaire (I-QOL) was
selected as the primary disease-speciﬁc HRQOL outcome meas-
ure for the incontinence treatment trial. The I-QOL is a 22-item
well-validated incontinence-speciﬁc instrument whose items
sum to give an index and three scale scores: the avoidance and
limiting behaviors scale (eight items), the psychosocial impact
scale (nine items), and the social embarrassment scale (ﬁve
items) [10,11]. Scores range from 0 to 100, with higher scores
indicating a better quality of life. To determine the MCID for the I-
QOL, we needed to know the mean difference in I-QOL scores that
would discriminate between women who rated their inconti-
nence as “much better” and “very much better” on the PGI-I and
women who did not achieve this degree of improvement.
Unfortunately, the I-QOL was not administered in the previous
trial, so this parameter was not available from the literature and
needed to be derived. Both I-QOL and 3-month PGI-I data were
available from another data set of 228 older women with incon-
tinence, all of whom were exposed to a nonsurgical intervention
for incontinence [20–22]. Using data from this cohort, the mean
change in I-QOL scores from baseline to 3 months, along with the
SD, was computed for the group of women who reported PGI-I
scores that were “much better” or “very much better” and for the
group of women who rated their symptoms as “a little bit better,”
“no change,” “a little bit worse,” “much worse,” or “very much
worse.” The MCID in incontinence-speciﬁc HRQOL was then
calculated as the difference in mean change scores on the I-
QOL between these two groups.
Deﬁning an MCID in Generic Preference-Based HRQOL
Choice of generic HRQOL measure
The choice of a generic preference-based HRQOL instrument for
the incontinence trial was guided by language, the psychometric
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and the likelihood that the domains of health captured by
each instrument would respond to changes in incontinence
symptoms. The EQ-5D-3L, the 12-Item Short Form Health Survey
(SF-12) (including its six-dimensional health state short form
[derived from the SF-36] [SF-6D] derivative), and Health Utilities
Index 3 (HUI-3) were all considered on the shortlist, having been
validated in English and French, with the trial requiring bilingual
measurement tools. On the basis of previous reports of the
psychometric properties of the EQ-5D-3L in patients with incon-
tinence, and its relative failure to correlate with and capture
changes in incontinence symptoms [7,8,23,24], the investigators
initially favored the use of the SF-12 and the HUI-3. The health
domains captured during transformation of the item responses
on the SF-12 questionnaire to SF-6D utility values are physical
functioning, role limitations due to physical health, bodily pain,
vitality, social functioning, role limitations due to emotional
problems, and mental health [25]. The domains captured by the
HUI-3 are ambulation, cognition, dexterity, emotional health,
hearing, pain, speech, and vision [26,27]. To choose between the
SF-12 and the HUI-3, ﬁve investigators (three health researchers/
physicians practicing incontinence and two outcomes research-
ers) blinded to the instrument names independently ranked each
domain represented by the SF-12 and the HUI-3 according to its
expected sensitivity to change in patients with incontinence, as
well as the relevance of each domain for the target older
community-dwelling population for the trial. A Likert scale with
six response options (very poor ¼ 0 to very good ¼ 5) was used to
determine consensus among members of the panel. All domains
represented by the SF-12 were ranked greater or equal to 3/5 by
respondents on both the expected responsiveness and pertinence
criteria, whereas only one domain from the HUI-3 was expected
to be moderately responsive (Table 1). Therefore, the SF-12 was
selected as the generic HRQOL outcome for the trial on which toTable 1 – Investigator rankings on the pertinence
and anticipated responsiveness of domains on the
SF-12 and HUI-3 for detecting improvements in
urinary incontinence.
Domain Pertinence to
older adults
with
incontinence
Anticipated degree
of responsiveness
to a continence
intervention
Ambulation 4.0 2.0
Cognition 3.7 0.0
Dexterity 3.3 0.3
Emotion 3.7 2.7
Emotional role
limitation
3.7 4.0
Hearing 4.0 0.0
Mental health 4.0 3.3
Pain 4.0 3.3
Physical function 4.3 3.7
Physical role
limitation
4.3 4.3
Social function 4.3 4.7
Speech 1.7 0.0
Vision 4.0 0.7
Vitality 3.3 3.0
Note. Each domain was ranked between 0 (poor) and 5 (very good)
by each of ﬁve investigators. The total score is the average of the
ﬁve scores.
HUI-3, Health Utilities Index 3; SF-12, 12-Item Short Form Health
Survey.test sample size calculations with the mapping approach pro-
posed by Ades et al. [14].
Mapping the incontinence-speciﬁc measure onto the generic
measure
As per Ades et al., we ﬁrst mapped the I-QOL onto SF-6D
derivatives from the SF-12, using data from the same external
source as the previous I-QOL analysis [20–22]. For the purpose of
comparing the construct validity and precision of the I-QOL
mapping coefﬁcient, we decided to use questionnaire data on
incontinence symptom severity and incontinence self-efﬁcacy in
a parallel mapping approach. Incontinence severity was meas-
ured with the International Consultation on Incontinence Ques-
tionnaire (ICIQ), a three-item instrument that assesses the
frequency and amount of incontinence, and the corresponding
degree of bother to the individual (on a 10-point visual analogue
scale) [28]. Scores from the three items are added to make a
summed score. Continence self-efﬁcacy was measured with the
Geriatric Self-Efﬁcacy Index for Urinary Incontinence (GSE-UI), a
12-item questionnaire that assesses an older person’s degree of
conﬁdence for preventing urine leakage under different sets of
circumstances and that correlates with symptom severity and
incontinence-speciﬁc quality of life [20,21].
The mapping exercise consisted of internal bootstrap split-
sample validation with 1000 iterations. For each iteration (i ¼ 1–
1000), the cohort (g) was randomly divided into development (di)
and validation (vi) groups. SF-6D health utilities, u(g), were
derived from responses on the SF-12 for each participant accord-
ing to published algorithms [25]. For each iteration, I-QOL, ICIQ,
and GSE-UI from di were individually regressed on SF-6D health
utilities, u(di), using a linear ordinary least squares (OLS) model, in
univariable and multivariable analyses adjusting for age. For
example, if the variable for I-QOL in the di was to be named Xdi,
and for age, Adi, for each ith iteration, we would generate 1000
(i ¼ 1–1000) βi0, βi1, and βi2 parameters with the following equation:
u dið Þ¼βi0þβi1Xdiþβi2Adi
Then, using the computed parameters (βi0, βi1, and βi2), an esti-
mated utility from the validation group, pvi, was computed for
each iteration:
pvi¼βi0þβi1Xviþβi2Avi
Correlation and goodness of ﬁt of the predicted SF-6D utilities
against the actual SF-6D utilities in the validation cohort were
assessed with Pearson correlation, mean absolute error, and root
mean square error. The precision of the mapping coefﬁcients for
the I-QOL, the ICIQ, and the GSE-UI (coefﬁcient divided by the
standard error of the estimate) was calculated according to Ades
et al. [14]. Higher values indicate better precision. Values around 5
for the precision of the estimated mapping coefﬁcient are consid-
ered as good as can be reasonably expected [14]. In sensitivity
analyses, Tobit and least absolute deviation models were run to
compare the performance of the estimates with the results of the
OLS models, but the OLS model yielded the highest precision. To
determine the MCID for the SF-6D, we multiplied the mapping
coefﬁcient derived in the OLS model for the I-QOL by the MCID
value for the I-QOL.
Sample Size Calculations
Sample sizes were calculated and compared using the MCIDs for
the global rating of improvement, the incontinence-speciﬁc
HRQOL measure, and the generic preference-based HRQOL meas-
ure. All calculations applied an alpha of 0.05 two-sided and a
power of 0.80. Figure 1 illustrates the ﬂowchart for each of the
three calculations. To determine the sample size for the global
rating of improvement of “much better” or “very much better,”we
Map IQOL onto SF-6D 
using baseline data; 
internal bootstrap split-
sample validation
Determine MCID for SF-6D from mapping 
exercise using the MCID for the IQOL
Determine MCID for the 
I-QOL using PGI-I data 
MCID unknown for incontinence-specific and 
generic HRQoL outcomes in incontinent 
patients
Must be derived from an external datasource
for the population of interest
MCID for incontinence known for a global 
rating of improvement outcome
Previous research indicates that the MCID 
corresponds to patient ratings of “much 
better” and “very much better” on the PGI-I 
Calculate sample 
size for global 
rating of 
improvement 
outcome
Calculate sample size 
for incontinence-
related HRQoL 
outcome using the 
MCID for the I-QOL
Calculate sample size for the generic HRQoL 
outcome by determining the number of participants 
required to detect the SF-6D MCID with 80% 
power, using bootstrapping methods
on an imaginary, expanding cohort of patients 
Establish that the sample size 
calculation will aim to detect a 
20% difference in proportions 
of participants reporting this 
MCID between the intervention 
and control groups, based on 
previous trial data
Fig. 1 – Flowchart for determining the minimal clinically important difference and sample size calculations for three HRQOL
outcomes. HRQOL, health-related quality of life; I-QOL, Incontinence Quality of Life questionnaire; MCID, minimal clinically
important difference; PGI-I, Patient Global Impression of Improvement questionnaire; SF-6D, six-dimensional health state
short form (derived from short-form 36 health survey).
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with an MCID rate of improvement in the control group esti-
mated at 6% on the basis of the previous trial [19]. To calculate
the sample size using the MCID for incontinence-speciﬁc HRQOL,
we used a two-sample t test with unequal variance on the basis
of I-QOL mean change scores and SDs that were obtained in the
previous analysis.
To calculate the sample size for generic HRQOL, we randomly
constructed an imaginary experimental group and a control
group for the incontinence trial, using the mean I-QOL score
with a normal distribution as observed in the external data (mean
74.9  24.3). On the basis of results of the MCID calculated for the
I-QOL, to the control group we added a normally distributed
random change variable (mean 1.91  14.19), corresponding to
the change values obtained from the cohort of 228 individuals
who did not report being “much better” or “very much better” on
the PGI-I. To the experimental group, we added a normally
distributed random change variable (mean 6.65  16.86), corre-
sponding to the I-QOL change values obtained from the individ-
uals who reported being “much better” or “very much better” on
the PGI-I. We simulated I-QOL change scores for the experimental
and control groups 1000 times according to this method. Each
time, the I-QOL change scores for each imaginary participant
were transformed to SF-6D utility value changes on the basis of
bootstrap regressions described earlier under the mapping exer-
cise. The difference in generic preference-based HRQOL was then
calculated as the difference in mean SF-6D utility value changes
between these two groups. We used the bootstrap process for
determining the difference in SF-6D utility values with different
sample sizes, from n ¼ 10 to 3000 per group, with increments of
n ¼ 10, using estimates from the mapping function. For each of the
1000 iterations, a Student t test for the difference in SF-6D utility
scores between the two groups was performed, and the overall
proportion of iterations in which the test was signiﬁcant was the
estimated power. Statistical signiﬁcance was deﬁned as P o 0.05.This last computation allowed us to evaluate the probability of
having a statistically signiﬁcant difference in SF-6D utility values
favoring the experimental group for a large array of sample sizes.
For each iteration, we recorded the minimal sample size required
to detect the MCID in SF-6D utility values with 80% power. All
statistical calculations were done with RStudio 0.97.248, R-3.0.2, as
an integrated development environment for R.Results
Data from 228 women aged 65 years and older (mean age 73.2 
5.8 years) who reported one or more episodes of involuntary
urinary loss during the previous 3 months were available for the
mapping exercise. All women had intact cognition, and approx-
imately 80% reported very good or good health on the SF-12. The
mean baseline scores on the ICIQ, the GSE-UI, and the I-QOL for
this cohort are listed in Table 2. The mean SF-6D utility value at
baseline was 0.78  0.15 (range 0.35–1.00).
The mean change in I-QOL scores according to 3-month
ratings of “much better” and “very much better” on the PGI-I in
the test cohort was an increase of 6.65  16.86 points. Women
who did not achieve this level of improvement on the PGI-I at 3-
month post-treatment had a mean change score of 1.91  14.19.
The MCID for the I-QOL was therefore set at 4.74 points.
The mapping estimates for the I-QOL, the ICIQ, and the GSE-UI
were all signiﬁcant (P o 0.05), and are given in Table 2. The
precision (SD/β) of the mapping estimate for the I-QOL was 4.43
compared with 3.33 for the incontinence severity scale (ICIQ) and
2.0 for the self-efﬁcacy index (GSE-UI). Compared with the ICIQ
and the GSE-UI, the I-QOL yielded the highest correlation (r ¼
0.39; Po 0.001) with the SF-6D and showed the best goodness-of-
ﬁt statistics (mean absolute error ¼ 0.108; root mean square error
¼ 0.134). Adjusting for age did not signiﬁcantly alter the model
estimates, nor did performing the analyses with a Tobit or least
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 9 2 – 2 9 8296absolute deviation model instead of an OLS model. Only the
univariable regression results using the OLS model are given in
Table 2. An MCID of 0.0126 in SF-6D utility values was determined
for generic HRQOL by plugging in the I-QOL MCID into the
mapping function for the SF-6D described in Table 2.
Comparison of Sample Size Requirements for Different HRQOL
Outcomes
The sample size required to detect the MCID in the global rating
of improvement was 52 per trial arm, 172 per arm to detect the
MCID on the incontinence-speciﬁc HRQOL measure, and 500 per
arm to detect the MCID in SF-6D utility values (Table 3). Figure 2
illustrates the power computations for different sample sizes to
be able to determine an MCID for generic preference-based
HRQOL using the mapping method.Discussion
The process of testing MCID determinations for three different
HRQOL outcomes of an incontinence treatment trial yielded large
differences in sample size, depending on whether a global rating
of improvement, an incontinence-speciﬁc HRQOL instrument, or
a mapping function for the SF-6D was used. The smallest sample
size of 52 patients per trial arm was obtained using the anchor-
based method rooting the MCID in patients’ subjective ratings of
improvement on a global rating of improvement scale. Trans-
posing the MCID from the global rating of improvement scale to
the I-QOL resulted in a requisite sample size of 172 patients per
trial arm, and mapping the I-QOL onto the SF-6D using a boot-
strapping method resulted in an estimated sample size of 500
participants per trial arm.
Previous research on conditions that primarily affect mental
health domains of HRQOL supports our experience with MCID
determinations for trial-based sample size estimation for
generic preference-based HRQOL outcomes. Although the
present analysis could not directly examine the sample size
required to conﬁrm an equivalent effect using the SF-12 alone—
because of missing data in the test cohort—a similar exercise
performed retrospectively among patients enrolled in a schizo-
phrenia trial suggests that the mapping method proposed by
Ades et al. affords slightly greater efﬁciency [12]. In the schiz-
ophrenia trial, in which retrospective sample size calculations
were based on the effect size measured by a disease-speciﬁc
preference-based HRQOL measure versus the SF-36, a fourfold
increase in sample size was ascertained for using the SF-36
alone, which is greater than the threefold increase observed by
converting the I-QOL to SF-6D values in the present study using
the mapping function proposed by Ades et al. In Lenert et al.’s
[12] analysis from the schizophrenia trial, the sample size
calculations were based on a change in SF-6D utility of 0.0285,
with an SD of 0.132. Mapping disease-speciﬁc MCIDs to obtain
SF-6D MCIDs in our analysis yielded half the target change in
utilities, a required difference of 0.0126 in SF-6D utilities. Our
value is also consistent with the gain of 0.0122 in SF-6D utilities
recorded by Brazier et al. [9] using a preference-based HRQOL
index developed from another incontinence-speciﬁc HRQOL
instrument, the King’s Health Questionnaire, in patients with
incontinence successfully treated with drug therapy. This MCID
value falls in the lower range of MCIDs for the SF-6D, ranging
from 0.010 to 0.048, detected by Walters and Brazier [29] in their
review of seven longitudinal studies for conditions other than
incontinence.
In principle, there are no major differences between planning
a study using HRQOL assessment and planning one using con-
ventional clinical outcomes [30]. In practice, however,
Table 3 – Comparison of sample size requirements.
HRQOL
outcome
Measurement
instrument
Expected
change in
the control
group
Minimal clinically
important difference
between the control and
intervention groups
Source of the change
estimate
Sample size
required per
group (two-
sided α 0.05,
80% power)
Global rating of
improvement
Patient global
impression of
improvement
scale (PGI-I)
6% A 20% difference in the
proportion of participants
rating their improvement as
much better or very much
better
Data from a previous
trial [19]
52
Improvement in
incontinence-
speciﬁc quality
of life
Incontinence
Quality of Life
questionnaire (I-
QOL)
1.91 14.19
(mean  SD)
point
improvement
on the I-QOL
4.74 points External data source,
expected improvement
in the intervention
group ¼ 6.65  16.90
(mean  SD)
172
Improvement in
generic
preference-
based quality
of life
(mapping
exercise)
12-Item Short
Form Health
Survey (SF-12)
0.005 utility
points on the
SF-6D
A gain of 0.0126 in SF-6D
utility values
Mapping exercise. I-
QOL mapping
coefﬁcient 0.00266 
0.0006 (precision* ¼
4.4333)
500
HRQOL, health-related quality of life; SF-6D, six-dimensional health state short form (derived from short-form 36 health survey).
* Mapping coefﬁcient divided by standard error of the mapping coefﬁcient.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 9 2 – 2 9 8 297researchers encounter greater difﬁculty achieving parsimonious
sample size for trials evaluating HRQOL. MCIDs are dependent on
the type of HRQOL instrument selected for the trial. Smaller effect
sizes result from using generic HRQOL measures that are poorly
responsive to small but important gains in disease-speciﬁc
HRQOL. For a given power and signiﬁcance level, the sample size
is inversely proportional to the square of the effect size, so
halving the effect size will quadruple the sample size [30]. Judi-
cious decisions must therefore be taken on the choice of disease-
speciﬁc and generic HRQOL instruments for the trial, and
whether or not a mapping function should be used to calculate
the MCID. We selected the SF-12 as the generic HRQOL instru-
ment for this trial, by examining the previous performance of
other HRQOL measures for incontinence, and through a modiﬁed
Delphi consensus among investigators knowledgeable to the
lived clinical realities of older women suffering from urine loss.Fig. 2 – Power for sample size calculations for generic HRQOL usinOur sample size calculations may have been different if we used
the EQ-5D-3L or the HUI-3.
One limitation to the calculations that were performed
involves the relatively small sample size (n ¼ 228) for the
mapping exercise, which may have increased uncertainty around
the estimates. Second, we used the I-QOL total score in the
regressions, rather than the item scores, which is the most
common and simplest form of model speciﬁcation used in
mapping exercises, but may result in a loss of sensitivity [31].
Subscales of the I-QOL were tested but did not yield better results.
Models other than OLS, Tobit, and least absolute deviation may
have yielded more precise estimates [31]. Finally, our analysis
assessed the sample size for HRQOL outcomes and meaningful
gains in health utilities only, which represent the Q in the QALY
denominator of the incremental cost-effectiveness ratio used in
health technology assessment. For a trial-based economicg the mapping method. HRQOL, health-related quality of life.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 9 2 – 2 9 8298evaluation, sample size calculations must consider the joint
distribution of costs and effects, and not infrequently, a trial
can be sufﬁciently powered to detect statistical differences in
treatment but insufﬁciently powered to detect statistical differ-
ences in costs, or vice versa, as shown in the review by Holling-
worth et al. [13]. Costs have skewed distributions, with increased
variance compared with some clinical outcomes, so the key to
ensuring adequate power calculations is to determine a differ-
ence in both costs and HRQOL effects when cost-utility is the
focus of sample size calculation [32].
In conclusion, our comparison of sample size calculations that
take into account the MCIDs for three different HRQOL outcomes
reveals that signiﬁcant discrepancies in sample size can be
obtained, even with mapping functions aimed at increasing
efﬁciency. Incontinence falls in a disease category in which mental
health dimensions of HRQOL are prominent, making generic
HRQOL poorly responsive to small but important gains in quality
of life. Other disease conditions that fall into this category may be
subject to similar challenges during sample size determinations
for treatment trials. Failure to account for adequate determination
of sample size for HRQOL outcomes is a potential pitfall that can
result in an inability to show a positive effect, despite evidence of
successful treatment. However, obtaining large samples is not
always simple or pragmatic in many trials. Future methodologies
for comparing meaningful gains in HRQOL across different disease
conditions are needed to overcome this challenge.
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